Abstract
Since its discovery in human blood plasma about 70 years ago, circulating cell-free DNA (cfDNA) has become an attractive subject of research as noninvasive disease biomarker. The interest in clinical applications has gained an exponential increase, making it a popular and potential target in a wide range of research areas.
cfDNA can be found in different body fluids, both in healthy and not healthy subjects. The recent and rapid development of new molecular techniques is promoting the study and the identification of cfDNA, holding the key to minimally invasive diagnostics, improving disease monitoring, clinical decision, and patients’ outcome.
cfDNA has already given a huge impact on prenatal medicine, and it could become, in the next future, the standard of care also in other fields, from oncology to transplant medicine and cardiovascular diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mandel P, Métais P (1948) Les acides nucléiques du plasma sanguin chez l’homme. Biologie 3–4:241–243
Cicchillitti L, Corrado G, De Angeli M et al (2017) Circulating cell-free DNA content as blood based biomarker in endometrial cancer. Oncotarget 8(70):115230–115243
Fleischhacker M, Schimdt B (2007) Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta 1775:181–232
Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61(4):1659–1665
Stroun M, Maurice P, Vasioukhin V et al (2000) The origin and mechanism of circulating DNA. Ann N Y Acad Sci 906:161–168
Stroun M, Lyautey J, Lederrey C et al (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313(1–2):139–142
Canzoniero JV, Park BH (2016) Use of cell free DNA in breast oncology. Biochim Biophys Acta 1865(2):266–274
Stötzer OJ, Lehner J, Fersching-Gierlich D et al (2014) Diagnostic relevance of plasma DNA and DNA integrity for breast cancer. Tumour Biol 35(2):1183–1191
Lui YY, Chik KW, Chiu RW et al (2002) Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 48(3):421–427
Elshimali YI, Khaddour H, Sarkissyan M et al (2013) The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14(9):18925
Swarup V, Rajeswari MR (2007) Circulating (cell-free) nucleic acids—a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 581(5):795–799
Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32(6):579–586
Giacona MB et al (1998) Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17(1):89–97
Tsumita T, Iwanaga M (1963) Fate of injected deoxyribonucleic acid in mice. Nature 198:1088–1089
Lo YM, Zhang J, Leung TN et al (1999) Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64(1):218–224
Snyder MW, Kircher M, Hill AJ et al (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164(1–2):57–68
Nagata S, Nagase H, Kawane K et al (2003) Degradation of chromosomal DNA during apoptosis. Cell Death Differ 10:108–116
Holdenrieder S, Stieber P (2004) Apoptotic markers in cancer. Clin Biochem 37:605–617
Nagata S (2005) DNA degradation in development and programmed cell death. Annu Rev Immunol 23:853–875
Karachaliou N, Sosa EA, Molina MA et al (2017) Possible application of circulating free tumor DNA in non-small cell lung cancer patients. J Thorac Dis 9(suppl 13):S1364
Stroun M, Lyautey J, Lederrey C et al (2001) Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells? Ann N Y Acad Sci 945:258–264
Van der Vaart M, Pretorius PJ (2008) Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 1137:18–26
Anker P, Stroun M, Maurice PA (1975) Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res 35:2375–2382
Van der Vaart M, Pretorius PJ (2007) The origin of circulating free DNA. Clin Chem 53:2215
Gardiner C, Harrison P, Belting M et al (2015) Extracellular vesicles, tissue factor, cancer and thrombosis—discussion themes of the ISEV 2014 Educational Day. J Extracell Vesicles 4:26901
Ho MW (2009) Intercommunication via circulating nucleic acids. Sci Soc 42:46–48
Tan EM, Schur PH, Carr RI et al (1966) Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45(11):1732–1740
Leon SA, Shapiro B, Sklaroff DM et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37(3):646–650
Shapiro B, Chakrabarty M, Cohn EM et al (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51(11):2116–2120
Lo YM, Corbetta N, Chamberlain PF et al (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350(9076):485–487
Rainer TH, Wong LK, Lam W et al (2003) Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem 49(4):562–569
Chang Y, Chia RH, Wu TL et al (2003) Elevated cell-free DNA detected in patients with myocardial infarction. Clin Chim Acta 327:95–101
Frank OM (2016) Circulating cell-free DNA differentiates severity of inflammation. Biol Res Nurs 18(5):477–488
Chan AK, Chiu RW, Lo YM et al (2003) Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem 40(Pt 2):122–130
Salvi S, Gurioli G, De Giorgi U et al (2016) Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther 9:6549–6559
Lin SY, Linehan JA, Wilson TG (2017) Emerging utility of urinary cell-free nucleic acid biomarkers for prostate, bladder, and renal cancers. Eur Urol Focus 3(2–3):265–272
Botezatu I, Serdyuk O, Potapova G et al (2000) Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 46(8 Pt 1):1078–1084
Casadio V, Calistri D, Salvi S et al (2013) Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. Biomed Res Int 2013:270457
Garzón M, Villatoro S, Teixidó C et al (2016) KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. Transl Lung Cancer Res 5(5):511–516
Papageorgiou EA, Karagrigoriou A, Tsaliki E et al (2011) Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med 17(4):510–513
Lo YM, Tein MS, Lau TK (1998) Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 62(4):768–775
Gerson KD, O’Brien BM (2018) Cell-free DNA. Screening for single-gene disorders and determination of fetal rhesus D genotype. Obstet Gynecol Clin N Am 45:27–39
Liao GJ, Gronowski AM, Zhao Z et al (2014) Non-invasive prenatal testing using cell-free fetal DNA in maternal circulation. Clin Chim Acta 428:44–50
Ashoor G, Syngelaki A, Poon LC et al (2013) Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 41(1):26–32
Chitty LS, Griffin DR, Meaney C et al (2011) New aids for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic features, charts of fetal size and molecular confirmation using cell-free fetal DNA in maternal plasma. Ultrasound Obstet Gynecol 37(3):283–289
Amicucci P, Gennarelli M, Novelli G et al (2000) Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem 46(2):301–302
Chitty LS, Bianchi DW (2013) Noninvasive prenatal testing: the paradigm is shifting rapidly. Prenat Diagn 33(6):511–513
Hill M, Barrett AN, White H et al (2012) Uses of cell free fetal DNA in maternal circulation. Best Pract Res Clin Obstet Gynaecol 26(5):639–654
Finning K, Martin P, Daniels G (2004) A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann N Y Acad Sci 1022:119–123
Fiorentino F, Bono S, Pizzuti F et al (2017) The clinical utility of genome-wide non invasive prenatal screening. Prenat Diagn 37(6):593–601
Ulrich BC, Cloud PP (2018) Cell-free DNA in oncology: gearing up for clinic. Ann Lab Med 38:1–8
Sozzi G, Conte D, Leon M et al (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21(21):3902–3908
Shao X, He Y, Ji M et al (2015) Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett 10(6):3478–3482
Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14(9):985–990
Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102(45):16368–16373
Holdhoff M, Schmidt K, Donehower R et al (2009) Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst 101(18):1284–1285
Alix-Panabières C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479–491
Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11(6):426–437
Cheng F, Su L, Qian C et al (2016) Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 7(30):48832–48841
Li J, Dittmar R, Xia S (2017) Cell-free DNA copy number variations in plasma from colorectal cancer patients. Mol Oncol 11:11099–11111
Soave A, Chun FK, Hillebrand T et al (2017) Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget 8:56398–56407
Husain H, Nykin D, Bui N et al (2016) Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology. Mol Cancer Ther 16:948–955
Li Z, Guo X, Tang L (2016) Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfate next-generation sequencing. Tumour Biol 37:13111–13119
De Mattos-Arruda L, Caldas C (2016) Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol 10(3):464–474
Heitzer E, Ulz P, Geigl JB (2015) Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61(1):112–123
Lewis AR, Valle JW, McNamara MG (2016) Pancreatic cancer: are “liquid biopsies” ready for prime-time? World J Gastroenterol 22(32):7175–7185
Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY et al (2018) The dawn of the liquid biopsy in the fight against cancer. Oncotarget 9(2):2912–2922
Sundaresan TK, Haber DA (2015) Does molecular monitoring matter in early-stage breast cancer? Sci Transl Med 7(302):302fs35
Yanagita M, Redig AJ, Paweletz CP et al (2016) A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung Cancer patients treated with Erlotinib on a phase II trial. Clin Cancer Res 22(24):6010–6020
Oxnard GR, Paweletz CP, Kuang Y et al (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20(6):1698–1705
Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447):108–112
Diaz LA Jr, Williams RT, Wu J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537–540
Schiavon G, Hrebien S, Garcia-Murillas I et al (2015) Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7(313):313ra182
Lallous N, Volik SV, Awrey S et al (2016) Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol 17:10
Azad AA, Volik SV, Wyatt AW et al (2015) Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 21(10):2315–2324
Siravegna G, Mussolin B, Buscarino M et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21(7):795–801
Morelli MP, Overman MJ, Dasari A et al (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731–736
Jänne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372(18):1689–1699
Sequist LV, Soria JC, Goldman JW et al (2015) Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372(18):1700–1709
https://molecular.roche.com/assays/cobas-egfr-mutation-test-v2/
Truszewska A, Foroncewicz B, Pączek L (2017) The role and diagnostic value of cell-free DNA in systemic lupus erythematosus. Clin Exp Rheumatol 35(2):330–336
Glebova KV, Veiko NN, Nikonov AA et al (2018) Cell-free DNA as a biomarker in stroke: current status, problems and perspectives. Crit Rev Clin Lab Sci 55(1):55–70
Snyder TM, Khush KK, Valantine HA et al (2011) Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 108(15):6229–6234
El Messaoudi S, Rolet F, Mouliere F et al (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424:222–230
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Ranucci, R. (2019). Cell-Free DNA: Applications in Different Diseases. In: Casadio, V., Salvi, S. (eds) Cell-free DNA as Diagnostic Markers. Methods in Molecular Biology, vol 1909. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8973-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8973-7_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8972-0
Online ISBN: 978-1-4939-8973-7
eBook Packages: Springer Protocols